Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus MYCHEL S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus MYCHEL S.
CHLOROMYXIN vs MYCHEL-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Sulconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
200 mg orally every 12 hours for 14 days
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
3-4 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
CHLOROMYXIN is not a recognized drug. No data available.
Renal: 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Antibiotic
Antibiotic